Journal of Clinical Oncology
Articles in this Issue
A retrospective, multicentric, observational, real-world evidence (RWE) study on cost impact, efficacy, and safety of generic palbociclib in HR+ve, HER2-ve metastatic breast cancer: An Indian perspective.
e13076 Background: Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has proven efficacy in managing hormone receptor-positive (HR+ve), HER2-...
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201.
7508 Background: No FDA approved treatments exist for relapsed/refractory (RR) AL Amyloidosis. Chimeric antigen receptor T-cell (CAR-T) is a novel approac...
A real-world study on first-line (1L) treatment for 46 advanced lung adenocarcinoma patients harbouring epidermal growth factor 20 insertion mutation (EGFR ex20ins).
e20652 Background: EGFR ex20ins is a rare mutation in lung adenocarcinoma. For this mutation, 1L standard of care(SOC) are mainly based on platinum - base...
Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.
4501 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1L maintenance + best supportive care (BSC) significantly prolonged overall survival (...
Clinical study on the assessment of first-line drug efficacy in advanced gastric cancer by monitoring circulating tumor cells through a self-developed microfluidic chip.
e15041 Background: Most gastric cancer patients are in advanced stages with poor prognosis and high mortality. How to improve the diagnosis rate, simply a...
Oncologists’ preferences for first-line (1L) treatment of ALK-positive metastatic NSCLC in the US: A discrete choice experiment (DCE).
e20631 Background: Trade-offs between efficacy, safety, and administration of 1L treatments for ALK+ mNSCLC are evolving and may influence shared decision...
Safety and efficacy evaluation of neoadjuvant chemotherapy without radiotherapy combined with sintilimab for locally advanced rectal cancer: Short-term results of a single-arm phase 2 trial.
e15657 Background: Sequential total mesorectal excision (TME) and adjuvant chemotherapy following neoadjuvant chemoradiotherapy (nCRT) are currently the s...
Trends in pediatric obesity-related cancers in the United States.
e22554 Background: To determine the trends and incidence in obesity associated cancers of young patients in the US over the last 20 years. Met...
Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.
2527 Background: QLS31905 is a Claudin18.2/CD3 bispecific antibody. Here we report the updated data of a phase 1 study of QLS31905. Methods:...
Ethnic disparities in clinical trials for FDA-approved drugs in colon cancer: A post-COVID era analysis (2020-2024).
e13816 Background: Equitable cancer treatment outcomes, as well as the generalizability of treatment application relies in part on diverse representation...
Utility of deep versatile classifier for accurate subtyping of lung adenocarcinoma using hematoxylin-eosin images.
e13700 Background: Subtyping lung adenocarcinoma using histopathology hematoxylin-eosin (H&E) images presents several challenges and can influence cli...
HIVreo: Recommendations on the management of people living with HIV and cancer (PLWHC).
e23234 Background: Despite advances in the fields of infectious diseases and oncology, cancer remains the primary cause of morbidity and mortality in peop...
Addressing gender disparities in oncology and hematology education: Insights from social media engagement analysis.
9039 Background: Gender disparities in professional visibility pose significant challenges to equity in oncology and hematology education. Women represent...
Radiotherapy followed by CAPOX and tislelizumab in MSS locally advanced rectal cancer with resectable metastases: Results of the MIRACLE-1 study.
e15524 Background: MSS tumors account for 95% of metastatic colorectal cancer and are characterized by a low response rate to immunotherapy. Emerging evid...
Survival outcomes following upfront surgery vs neoadjuvant chemotherapy for triple-negative and HER2-positive T1c and T2 breast cancer: A retrospective, population-based cohort study.
e12592 Background: Neoadjuvant systemic therapy (NST) is the guideline-concordant approach for HER2-positive(+) and triple negative (TN) breast cancers ov...
Beyond the clinic: Comprehensive assessment of time burdens in cancer care.
11011 Background: Managing cancer care can be highly demanding, consuming time and energy. Measuring this time has been limited to date. We sought to comp...
Analysis of quality-of-life outcomes in patients with head and neck squamous cell carcinoma.
e23208 Background: Patients with head and neck squamous cell carcinoma (HNSCC) are known to experience decline in quality of life due to the side effects...
Updated prostate cancer risk groups by PSMA-PET PROMISE (PPP2): Results from an international multi-centre registry study.
5045 Background: We previously established prognostic two-tier risk nomograms based on PSMA-PET and Prostate Cancer Molecular Imaging Standardized Evaluat...
Precision medicine research on chemo-immunotherapy combination treatment for locally advanced or metastatic non-small cell lung cancer based on deep plasma proteomics.
2552 Background: For locally advanced or metastatic non-small cell lung cancer (NSCLC) patients lacking specific genetic mutations, chemotherapy combined...
Impact of sociodemographic factors and Medicaid expansion on postoperative outcomes for glioblastoma, 2004-2021.
1614 Background: Glioblastoma (GBM), the most aggressive primary brain tumor in adults, has a median survival of ~15 months despite treatment and exhibits...
Results of phase III clinical trial of novel biosimilar of pembrolizumab (RPH-075).
9558 Background: Pembrolizumab is a high-affinity humanized antibody to the PD-1 receptor. This study investigated the efficacy and safety profile of RPH-...
Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.
5082 Background: Multiple reports suggest that Black patients with mCRPC have different responses to radiation, immunotherapy, chemotherapy, and secondary...
Safety and efficacy of the EZH1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): A multicenter phase I trial.
10003 Background: Valemetostat tosylate (DS-3201b; valemetostat) is a first-in-class dual inhibitor targeting the epigenet...
Evaluation of HER2 expression in prostate cancer among Mexican patients.
e17059 Background: Prostate cancer is one of the main types of cancer in men, specifically in Mexico there is an increasing trend in incidence in the last...
Rates of early mortality in acute promyelocytic leukemia patients: A SEER-based study.
e18500 Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that often presents with overt bleeding, thrombocytopen...